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Recombinant cytokine-like endothelial monocyte-activating polypeptide II (EMAP II) and antiandrogen flutamide target differ-
ent mechanisms of growth of androgen-dependent prostate cancer (PC). The aim of this study was to clarify whether combined 
treatment with EMAP II and flutamide is more effective than monotherapy with regard to retardation of PC progression. Materi-
als and Methods: Antitumor effects of EMAP II (10 µg/kg b.w./d, s.c., 3d), or flutamide (10 mg/kg b.w./d, per os, 3d), or their 
combination were studied in CBA male mice bearing human androgen-dependent PC xenografts for 7 days. Androgen-dependent 
phenotype of the tumors was verified in preliminary castrated mice. The xenografts were weighed and underwent a histopathologic 
examination. The results were compared with those of non-treated mice. Results: EMAP II and flutamide used separately inhibited 
growth of the xenografts by 74% and 53% respectively. Both drugs caused destructive changes in malignant epithelial cells along with 
leukocyte infiltration of the tumor. Combined treatment inhibited tumor growth by 85%, and was more effective than monotherapy 
with regard to morphological changes. Conclusions: This study demonstrates cooperative inhibitory effect of EMAP II and flutamide 
on growth and morphology of human PC xenografts that could represent a new modality of palliative treatment of this disease. 
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�uring the past few decades many countries regis-
tered a dramatic increase in the incidence of prostate 
cancer �PC� [�]. In Europe and North America� this life-
threatening disease �ecame the most common cause 
of tumor-related death in the elderly male population 
[���]. The risk of PC development depends on age� eth-
nic group� geography of living� family history� lifestyle� 
dietary pattern etc. The num�er of estimated new PC cas-
es in the USA was ��7 7�� in ���� [5]. Ukraine �elongs 
to the group of countries with a relatively high rate of di-
agnosed PC: from ���� to ���8� the num�er of patients 
increased from �7 ��� to �8 �5� ��y 65%� [6].
According to clinical characteristics PC was proposed 
to divide into aggressive phenotype which prevails 
in 55�65 years old men� and so-called insignificant� e.g.� 
a life-nonthreatening low-grade cancer� which is usually 
diagnosed in men around 75�8� years old [7]. Clinical 
management of an aggressive PC phenotype requires 
active treatment using surgery �radical prostatectomy� 
castration�� radiation and/or drug therapy. Maximum 
androgen �lockade provides effective palliative ther-
apy of PC. Successful com�ined hormonal treatment 
of androgen-dependent PC includes administration 
of LH RH agonists and androgen receptor antagonists 
�cyproterone acetate� flutamide� �icalutamide�� and 
it seems to �e the most effective as compared to mono-
therapy� especially in cases of advanced PC and meta-
static process [�� 8]. In the meantime� despite an initial 
transient positive response to androgen deprivation the 
disease relapses within a few years due to progression 
to androgen-independent phenotype of the tumor. 
This occurs �ecause androgen a�lation affects only 
androgen-dependent PC cells with no effect on andro-
gen-independent cell clones. For this reason hormonal 
treatment of PC should �e com�ined with drugs targeting 
oncogenes� growth factors� etc. With this regard some 
polypeptide components of aminoacyl-tRNA synthetase 
complexes� such as endothelial-monocyte activating 
polypeptide II �EMAP II�� could provide new possi�ilities 
for antitumor therapy [9].
EMAP II is the extracellular cytokine-like derivative 
of the auxiliary protein p�� which is associated with 
multisynthetase complex in mammals. This polypeptide 
is produced intracellulary during tissue lesion due to pro-
teolytic cleavage of endogenous p��� and its aminoacid 
residue sequence corresponds to the C-terminal moiety 
of p��. EMAP II is known as a multifunctional protein 
showing various activities. Upon its cleavage and extra-
cellular release� EMAP II �ecomes involved in the inflam-
mation process� stimulates apoptosis� demonstrates 
antiangiogenic and pro-coagulation effects� and sensi-
tizes tissues to the tumor necrosis factor-α� etc. [����6]. 
EMAP II was shown to inhi�it growth of glioma� human 
sarcoma� and pancreatic cancer in animal research [��� 
�5� �7��9]. Previously we have found an a�ility of recom-
�inant EMAP II to suppress the growth of human pros-
tate adenocarcinoma in mouse xenograft model [��]. 
Based on the a�sence of �lood supply of the xenografts 
it was postulated that this effect was caused �y stimula-
tion of apoptosis and pro-inflammatory activity of the 
EMAP II. We hypothesized that its antitumor effect might 
�e augmented �y com�ined administration with flutamide� 
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nonsteroidal androgen receptor antagonist. In this study� 
we compared the effects of separate and com�ined treat-
ment with EMAP II and flutamide on the growth and mor-
phology of androgen-dependent human PC xenografts.
MATERIALS AND METHODS
EMAP II preparation. Recom�inant EMAP II was 
cloned and expressed in E. coli essentially as we de-
scri�ed in details previously [��]. Briefly� the �NA frag-
ment encoding human mature EMAP II ����6-K���� was 
cloned in pET��a plasmid �Novagen�� and transforma-
tion of E. coli strain BL����E�� has �een done. The pres-
ence of specific �NA insert was confirmed �y restriction 
mapping and �NA sequencing. After � h induction 
of EMAP II overproduction with � mM isopropyl-β-
�-thiogalactopyranosid �IPTG�� �acterial cells were 
harvested �y centrifugation and disrupted �y ultra-
sonication in a �uffer containing �.� mM phenyl-
methylsulfonyl fluoride �PMSF�. EMAP II was isolated 
�y metal chelate column chromatography on Ni-NTA 
agarose �Qiagen� and eluted with ��� mM imidazole 
in 5� mM NaH�PO� �uffer �pH 8.�� with �.5 M NaCl 
and �.�5% Tween ��. The mature EMAP II ��69 a.a.� 
m.w.�8 5�5 �a� pI 6.�6� was o�tained �y specific cleav-
age with enterokinase and purified up to 98% purity 
grade as confirmed �y S�S gel electrophoresis. 
Animal experiments design. An animal research 
protocol was approved �y the Animal Care Committee 
at the V.P. Komisarenko Institute of Endocrinology and 
Meta�olism. Six-days the mouse renal su�capsular 
assay [��] was adapted to mature CBA male mice 
�����5 g �.w.�. They were �red and housed in the local 
animal care facility� and were supplied with standard 
diet and tape water ad libitum.
The PC tissue specimens were taken from four human 
patients �6��7� year old� during radical prostatectomy 
in the Oncourology �epartment� Institute of Urology 
�Kyev� Ukraine� after preliminarily o�taining their informed 
consent approved �y Institutional Bioethics Committee. 
A patient’s anonymity was carefully protected. The pa-
tients did not take neoadjuvant therapy �efore surgery. 
The tumors were identified �y pathologist as adenocar-
cinomas �the Gleason scores ranged from 5 to 7�. The 
tissue specimens were placed into Eagle’s Minimum Es-
sential Medium �Serva�� containing Hanks salts� HEPES� 
calf em�ryonic serum� �enzylpenicillinum ��.� U/ml� and 
streptomycinum ���� mg/ml� at �.�°C and delivered to the 
la�oratory on ice. On the next day� they were dissected 
into �.9���.�� mg pieces� and two grafts were implanted 
under the left kidney capsule of normal or castrated im-
mediately prior to transplantaion male mice using chloral 
hydrate for anaesthesia.
Non-castrated mice prepared for the drug treatment 
were divided into four groups �each of ����8 mice�. 
In the first one� EMAP II solution was diluted with saline 
immediately �efore using and injected su�cutaneously 
into the flank on the �th�6th days after tumor transplanta-
tion at a daily dose of ��.� mg/kg �.w. At the same terms� 
the second animal group was given flutamide as grinded 
ta�lets of Flutafarm �Farmak� Ukraine� suspended 
in �orfman’s gel ��.5% car�oxymethyl cellulose sodium 
salt� �.�% Tween 8�� �.9% �enzyl alcohol in saline� per 
os using feeding tu�e at a daily dose of ��.� mg/kg �.w. 
A com�ination of EMAP II and flutamide at the same 
doses was applied to the third animal group. Control 
mice were treated with vehicles according to mentioned 
treatment time-schedule. The next day after �-day 
treatments� the mice were euthanized with overdosing 
diethyl ether� and the xenografts were removed and 
weighed. Net tumor growth during experiment was 
calculated �y su�tracting final xenograft weight from 
initial one. Antitumor activity of tested drugs was evalu-
ated on the �asis of differences in gain of the xenograft 
weights �etween experimental and control groups.
Histopathological studies. The xenografts were 
processed in the routine manner� that is they were fixed 
in �% paraformaldehide� then paraffin-em�edded� and 
5 μm thick sections were prepared. The sections were 
stained with hematoxylin-eosin or hematoxylin-Schiff 
reagent and underwent histopathological examination 
using the microscopes Leіka �ME �Leika Microsys-
tems� Germany�.
Statistics. The results were compared with those 
of control �treated with vehicles� or castrated animals. 
Student’s t-test was used for statistical analysis.
RESULTS
Tumor xenografts growth. �uring the o�serva-
tion period� all mice demonstrated good tolerance 
to EMAP II and flutamide treatments with no visi�le 
changes in �ehavior� food and water consumption� and 
�ody weight in comparison with control group. By the 
end of experiment� the average tumor xenograft weight 
in control group was dou�led �Ta�le�. The xenografts 
harvested from castrated animals have demonstrated 
four-fold inhi�ition of the tumor growth. The same 
effect was o�served after EMAP II injections� while 
flutamide at the selected dose inhi�ited transplant 
growth almost twice. Maximum effect regarding xe-
nograft growth �85.�% inhi�ition� was o�tained after 
�-day com�ined treatment with EMAP II and flutamide.
Table. Effects of castration, and separate or combined administration 
of EMAP II and flutamide on growth of human PC xenografts in mouse renal 
subcapsular test (M ± m)
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1 Control 16 31 1.00±0.01 1,81±0.11 81.0 100
2 Castrated 12 24 1.03±0.02 1.23±0.09* 19.4 24.7
3 EMAP II, 10 mg/kg/d 18 36 1.02±0.01 1.23±0.05* 20.6 25.9
4 Flutamide, 10 mg/kg/d 13 26 1.01±0.01 1.39±0.07* 37.6 47.4
5 EMAP II, 10 mg/kg/d + 
flutamide, 10 mg/kg/d
12 24 1.01±0.01 1.13±0.08* 11.9 14.8
*p < 0.05 as compared with control.
Histopathological studies. Tissue sections 
of control xenografts allowed to grow for 7 days were 
characterized �y heterogenic distri�ution of prolifer-
ating malignant epithelial tissue� which formed the 
taenias or acinar structures �Figure� a�. The acinar 
epithelium formed multiple layers and was featured 
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�y cellular polymorphism and metaplasia. Malignant 
epithelial cells appeared polygonal or spindle-shaped. 
Enlarged and cleared oval nuclei were stretched 
toward lumen and contained nucleoli. �etritus and 
round-shaped desquamated epithelial cells were 
present inside some acinar lumens. An enlargement 
of stromal tissue due to edema was o�served. The 
xenografts from one patient contained a lot of non-
functioning neogenic capillaries situated closer to the 
xenograft’s margin. There were edema and destruc-
tive changes of stromal tissue� and fi�rinoid swelling 
mainly in the central zone of some xenografts. Moder-
ate leucocytes infiltration through stromal and some 
epithelial components� as well as marginal leukocyte 
accumulation around xenografts� were o�served.
Histological sections of PC samples from castrated 
mice showed atrophy of malignant epithelium along with 
an increase of incidence of karyopyknotic cells that evi-
denced the tumor dependency on androgen stimulation.
Histopathological study revealed significant degen-
erative changes and necrotic death of many tumor cells� 
stimulation of apoptosis �significant increase in num�er 
of apoptotic �odies�� an enlargement of necrotic areas 
and an enhancement of the leukocyte infiltration in the 
transplants exposed to EMAP II �Fi gure� b�. There was 
a noticea�le decrease in a num�er of acinar epithelial 
layers. Malignant epithelial cell volumes decreased� 
the majority of the nuclei did not contain the nucleoli. 
There was enhancement of leukocyte invasion into 
epithelial and stromal structures. Some epithelial cells 
developed round shape� plenty of them were separated 
from epithelial layer and translocated to a lumen. The 
stroma appeared similarly to the control.
Figure �c� illustrates the effect of flutamide treat-
ment on histological appearance of the xenograft. 
�ue to flutamide-induced atrophy and destruction 
of tumor cells� a num�er of epithelial layers decreased 
significantly. Spindle-shaped epithelial cells were laid 
on �asal mem�rane� and they contained more hyper-
chromic and pyknotic nuclei as compared to control. 
Leukocyte infiltration was less evident in comparison 
with that of EMAP II. There were necrotic changes 
of the stroma in the central area of some xenografts.
A cooperative effect of com�ined EMAP II and 
flutamide treatment on the xenograft histological ap-
pearance was found� consistent with maximum tumor 
growth retardation. This treatment modality resulted 
in the most evident atrophy and destruction of tumor 
tissue. In many acinar structures� epithelial layer was 
quite thin. Oval-shaped epithelial cells� containing 
dense cytoplasm and pyknotic nucleus along with 
signs of fragmentation and formation of apoptopic 
�odies occurred more often than after separate ad-
ministration of EMAP II or flutamide. 
a b
c d
Figure. Histological sections of the human PC xenografts in a mouse model. The animals were sacrificed at the 7th day after tumor 
tissue transplantation under the CBA mouse kidney capsule. The PC tissue sections were stained with hematoxylin-Schiff reagent. 
Bar� �� μ. a� The control xenograft. Malignant epithelial cells contain enlarged and cleared nuclei with nucleoli; b� The xenograft 
appearance after treatment with ЕМАР II� �� μg/kg �.w./d� s.c.� during �th�6th days after transplantation. Note loosened epithelium� 
periacinar edema� reduction of malignant epithelial cells size� and nuclear hyperchromatism. The nucleoli are presented only in a few 
epithelial cells. There is an enhanced leukocyte invasion into epithelial and stromal structures; c� The xenograft appearance after 
treatment with flutamide� �� mg/kg �.w./d� per os� during �th�6th days after transplantation. Note significant malignant epithelium 
atrophy. �� Lumen of the acinus; �� dilated capillary; d� The effect of com�ined treatment with ЕМАР II and flutamide at the a�ove 
mentioned doses and terms. There are sharp malignant epithelium atrophy� pericellular and periacinar edema� presence of hyper-
chromatic and pyknotic epithelium nuclei� an enhanced leukocyte invasion into epithelial and stromal structures.
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DISCUSSION
Flutamide is widely used clinically for palliative 
treatment of PC [�� 8]. Using gene expression-�ased 
�ioluminescence imaging of the androgen receptor 
signaling in the prostate tumor xenografts it was shown 
that flutamide significantly inhi�its androgen receptor 
function and its association with co-activators in mice 
[��]. In the present study� we tested whether flutamide 
is capa�le to enhance the inhi�itory effect of recom-
�inant cytokine-like polypeptide ЕМАР II on growth 
of human PC first generation transplants in the male 
mouse model. Effects of com�ined administration 
of these drugs on PC growth and morphology were 
not studied till now. 
All tumors used in our study pertained to andro-
gen-dependent phenotype that has �een confirmed 
�y striking retardation of the xenograft growth due 
to androgen deprivation caused �y preliminarily cas-
tration of the animals. Leukocyte accumulation in the 
xenografts grown in non-castrated mice indicated 
immune response� which is natural �ecause CBA mice 
represent immunocompetent strain. However� short-
term xenograft test rules out the transplant rejection. 
It is o�vious that xenografts devoided �lood circu-
lation experienced hypoxia and nutritional deficiency. 
Histopathologic study was decisive for evaluation 
of the drug effects �ecause leukocyte infiltration and 
hypoxia-induced oedema of the xenograft stroma 
could distort quantification of antitumor activity �ased 
on the xenograft weight changes. 
The findings of this study demonstrate an addi-
tive effect of flutamide concerning antitumor activity 
of ЕМАР II in mice �earing androgen-dependent human 
PC transplants with regard to the xenograft growth and 
morphology. Com�ined treatment turned out even more 
effective than castration� pro�a�ly due to �lockade 
of the tumor androgen receptor which could �e acti-
vated �y adrenal androgens remained after castration.
CONCLUSIONS
A cooperative antitumor effect of recom�inant 
cytokine-like polypeptide ЕМАР II and flutamide against 
androgen-dependent human PC xenografts in the mouse 
renal su�capsular test might �e considered in the devel-
opment of new therapeutic modality for prostate cancer 
�ased on com�ined administration of these drugs.
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